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Several countries have adopted the IAEA’s method to establish their 
own national auditing networks. Further development is being 
considered to check not only the reference condition, i.e.beam 
calibration, but also non-reference conditions, such as irregularly 
shaped and wedged beams, rotational, helical or not intensity 
modulated RT beams(Table), proton therapy beams. 
 
Reference Region Average SD (%) 
Gillis et al., 2005 
ESTRO-QUASIMODO 
Europe 1.014 
0.997 
1.6 
3.6 
Tomsej et al., 2005 
GORTEC 
Europe 0.992 3.9 
Ibott et al., 2006 
RPC-RTOG 
US 0.99 
0.99 
8 
7 
Tomsej et al., 2007 
ESTRO-OECI 
Europe 0.966 
0.978 
2.4 
1.5 
 
ESTRO booklet 9 Guidelines for the verification of IMRT, Table 7.3: 
Results from studies of the accuracy of dose determinations of IMRT 
treatments. 
Recent advances in radiotherapy focus on the need for a systematic 
quality assurance program that balances patient safety and quality 
with available resources. External audit programmes for radiotherapy 
QA are also effective. Both postal dosimetry audit and clinical trial 
radiotherapy QA, especially for advanced technologies, in 
collaboration with global networks, will serve to enhance patient 
safety and quality of care. 
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Purpose/Objective: The accuracy of photon dose calculation in the 
out-of-field regions is often neglected despite its importance for 
organs at risk and peripheral dose evaluation. The present work 
assessed the dose calculation accuracy of the Anisotropic Analytical 
Algorithm (AAA) and the Acuros XB algorithms implemented in the 
Eclipse treatment planning system, in the regions shielded by the jaw, 
or the MLC, or both MLC and jaw for flattened (6 and 10 MV) and 
unflattened (6 and 10 FFF MV) beams. The largest difference to out-
of-field dose coming from the two beams (flattened and unflattened) 
is due to the head scatter, where for FFF beams a lower contribution 
is expected due to the lack of flattening filter scattering. 
Materials and Methods: Six and 10 MV, flattened and unflattened 
beams, were from a TrueBeam (Varian Medical Systems, Palo Alto, 
USA), equipped with Millennium 120-MLC. Depth doses in water, out of 
the field, parallel to the field edge were acquired at 1, 2, 3, 5 and 10 
cm distance from the field edge. Lateral field side was set as 1, 5 and 
10 cm. The following shielding modalities were used to set the beam: 
(1) jaw defined field (MLC retracted); (2) MLC defined field (jaws set 
to 40x35 cm2); (3) jaw+MLC defined field (both positioned at the field 
edge). Measurements were acquired with a 0.125 cm3 ion chamber. All 
measurements were then compared with the corresponding AAA and 
Acuros XB calculations (version11.0.21) in water. 
Four volumetric modulated arc therapy plans (in the RapidArc form) 
were optimized in a water equivalent phantom, PTW Octavius, in a 
way to have a region always shielded by the MLC or jaw+MLC during 
the delivery. A structure was delineated mimicking the target with 
the anterior part of a ring shape of 6 cm external diameter and 3 and 
4 cm thickness (two optimizations); the organ to spare was a 
cylindrical volume at distance of 0.5 cm from the target and with a 
radius of 2 and 1 cm, respectively. Doses to seven points located in 
the shielded region and in the target like structure were measured 
with a 0.125 cm3 ion chamber. Results were compared with the AAA 
and Acuros XB calculations in terms of absorbed dose in a volume as 
the ion chamber sensitive volume.  
Results: In general a good agreement between calculation and 
measurements was found for both algorithms. From depth dose 
analysis the 10 FFF beam resulted, as expected, to offer the lowest 
out-of-field dose. The overall average difference (all energies and 
shielding methods) between measurements and calculations were 
below 0.6% for AAA and below 0.8% for Acuros XB. 
From RapidArc plans analysis the average differences between 
calculation and measurement in the shielded region were -0.9%±0.4% 
and -3.1%±1.3% for AAA and Acuros XB, respectively, relative to the 
mean target dose value. Differences in the target structure were of -
0.5%±2.3%, -0.7%±2.3% for AAA and Acuros XB, respectively. 
Conclusions: The high accuracy required to properly evaluate the out-
of-field dose can be achieved with the analysed algorithms, AAA and 
Acuros XB that showed an accuracy degree in those low dose regions 
similar, relatively to in-field dose, to what obtained for open beams.  
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Purpose/Objective: Assessment of acceptable target dose conformity 
in plans with multiple prescription levels is a challenge due to the 
inevitable over/underdosage at the borderline between dose levels. 
Here, we propose a tool for the evaluation of target dose in treatment 
plans with multiple dose levels, providing a possible contribution to 
level 3 reporting in ICRU report 83. We illustrate the potential of the 
tool in identifying a single plan as suboptimal and identifying a 
systematic change in planning priorities in our institution between 
2010 and 2012. 
Materials and Methods: Dose painted treatment plans with five dose 
levels (DP plans) were evaluated for 20 head and neck cancer 
patients. As a complement to structure specific dose parameters, plan 
specific parameters describing the target dose were used for the 
quality assessment tool. The quality value Q was the basis for the 
evaluation and was used to obtain quality volume histograms (QVH): 
  
A one-dimensional measure, the quality factor, QF, has previously 
been used1 to evaluate target dose: 
 where n is the number of voxels and Qp is the qualityvalue in voxel p. 
We propose to supplement this measure with a 2D QVH tool that is 
based on the experience from previous similar treatment plans. For 
each Q value, the median relative volume, V, and interquartile range 
(iqr) among the group of historical plans was found. An area on the 
QVH corresponding to median(V) ±1.45*iqr was outlined, which in case 
of normal distribution includes 95% of the plans. When evaluating the 
QVH of a new plan, this tool can be used to identify poorer than usual 
dose conformity. We overlaid the QVH plots of 13 clinical 
hypopharyngeal plans from 2010 with 13 hypopharyngeal plans from 
2012, and used the QVH tool to identify a change in plans over time. 
Results: Figure 1 illustrates that one of 20 H&N DP plans was 
identified as suboptimal by the QVH tool, even though it met all 
planning constraints. The plan had more overdosage than what should 
be expected, and was reoptimized and improved (Figure 1, thick dark 
line). The plan QF decreased from 0.056 to 0.045, corresponding well 
to the group average: mean QF 0.047 (range 0.039-0.056). 
Comparison of the 2010 and 2012 plans with the QVH tool clearly 
demonstrated that current treatment plans have less underdosage at 
the expense of more overdosage when compared to the 2010 plans. 
This change is not associated with a change in QF. 
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 Conclusions: The QVH tool provided a method to assess how well the 
prescription dose to target volumes was met in the treatment plans of 
this study. The tool could be used to identify a single suboptimal plan 
and to compare groups of plans which cannot be distinguished by 
means of the one-dimensional QF value. The QVH tool could, for 
example, be used in the quality assurance of a multi-centre trial, and 
for visualizing the learning curve of multiple dose level treatment 
planning in routine clinical practice. It could provide a valuable 
contribution to level 3 reporting of ICRU report 83. 
1 Duprez et al. IJROBP 2011 
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Purpose/Objective: Recently, a Cyberknife (CK) with an MLC became 
available. A key CK feature is easy delivery of non-coplanar (n-CP) 
beams. Objective evidence for added value of such beams is mostly 
lacking, partly because a common TPS for both systems did not exist 
until recently. Moreover, commercial TPS require trial-and-error 
tweaking of plan parameters for individual patients, making the 
outcome of planning highly user-dependent. With the recent MLC 
introduction, our in-house algorithm for multi-criterial plan 
optimization, iCycle, can now also optimize IMRT for CK. With iCycle, 
plan generation is fully automatic (no per patient tweaking), allowing 
objective comparison of treatment strategies in a single TPS. In this 
study we used iCycle to compare n-CP CK and CP linac approaches for 
prostate cancer. 
Materials and Methods: For 10 patients, iCycle was used to 
automatically generate plans with optimized profiles and beam angles 
for the CK and a conventional linac, emulating HDR brachytherapy 
dosimetry. For the linac, the beam search space contained 72 
coplanar orientations (separation 5°). For both systems, Pareto 
optimal IMRT plans were automatically generated, containing 1-30 
optimized beam directions (60 plans per patient), delivering 4 
fractions of 9.5Gy. Low rectum dose was the highest priority OAR 
objective for generating optimal plans within hard constraints, 
following achievement of a PTV V95 of ±99%.Other OARs considered 
were urethra, bladder, penis, scrotum, and femoral heads. 
Results: Both for the CK and the linac, PTV V95 was >99%. For both 
systems, plan quality did heavily depend on the number of beams 
included in the plan. For CK, rectum Dmean, V40Gy, V60Gy, and D1cc in 25 
beam plans were on average 50%, 67%, 71% and 15% lower than in 11 
beam plans, for equal PTV coverage. For 25 beam plans, differences 
between CK and linac in PTV- and peripheral zone Dmean and D98% were 
on average smaller than 0.3% (p>0.05), while the CK plans had 
18.5±8.0%, 23.2±14.1%, 21.4±20.8%, and 3.0±3.8% lower rectum Dmean, 
V40Gy, V60Gy, and D1cc, respectively (p=0.002; for all 10 patients, all 4 
rectum parameters were lowest for CK). There were no differences in 
urethra Dmean and D2% and in bladder Dmean. Bladder D2% was 2.5% lower 
for CK (p=0.002). For the femoral heads, Dmean and D2% were 20% and 
10% lower in CK plans (p=0.002). In all plans, penis/scrotum Dmean and 
D2% were lower than 2Gy and 4Gy, respectively, as imposed by hard 
constraints. Delivery time of 25 beam CK plans was 18.1±0.5 min, 
including imaging and correction for each beam.  
Conclusions: Non-coplanar hypo-fractionated treatment of prostate 
cancer with a Cyberknife did strongly reduce rectum dose compared 
to coplanar linac plans. For both systems, 25 beam plans greatly 
improved rectum dose compared to 11 beam plans. Due to the MLC, 
25 beam CK non-coplanar plans could be delivered in only 18 minutes, 
including image-guided beam-tumour alignment before delivery of 
each beam. 
   
OC-0432   
Evaluating the feasibility of sparing CNS structures to reduce acute 
fatigue from IMRT for head and neck cancer 
J.A. Dean1, G. Smyth1, J.P. Morden2, E. Hall2, K.J. Harrington3, C.M. 
Nutting3, S.L. Gulliford1 
1The Institute of Cancer Research and The Royal Marsden NHS 
Foundation Trust, Joint Department of Physics, Sutton, United 
Kingdom  
2The Institute of Cancer Research, Clinical Trials and Statistics Unit, 
Sutton, United Kingdom  
3The Institute of Cancer Research and The Royal Marsden NHS 
Foundation Trust, Head and Neck Unit, London, United Kingdom  
 
Purpose/Objective: The PARSPORT trial (CRUK/03/005) demonstrated 
that parotid-sparing intensity-modulated radiotherapy (IMRT) achieved 
a significant reduction in severe xerostomia compared with 
conventional radiotherapy in patients being treated for squamous cell 
carcinoma of the head and neck. An unexpected result of the trial was 
a significantly higher incidence of acute fatigue in patients 
randomised to receive IMRT. Analysis of trial data has shown that this 
correlates with increased radiation doses to central nervous system 
(CNS) structures. Based on this analysis potentially valuable dose-
volume constraints were implemented as inverse treatment planning 
objectives to explore the ability to reduce the dose to CNS structures 
without compromising the dose distributions to the tumour and 
normal tissues. 
Materials and Methods: A retrospective planning study was performed 
for 9 local patients – 3 each with tumours of the hypopharynx, 
oropharynx and nasopharynx. Relevant additional CNS structures were 
delineated by an experienced radiation oncologist. A 7-field inverse 
planned IMRT technique was used to produce clinically acceptable 
plans. Maximum dose-volume objectives were then introduced for the 
brainstem and cerebellum, the plans re-optimised and the level of 
cerebellum and brainstem dose-sparing assessed. The effect of the 
primary disease site on the ability to meet the constraints was 
investigated. 3D dose analysis was performed to assess the differences 
in the dose-distributions in other regions upon introduction of the 
constraints. 
Results: Introducing the additional CNS constraints into the treatment 
plan optimisation allowed significant dose-sparing to the cerebellum 
and brainstem to be achieved without compromising clinical plan 
assessment measures. Figure 1 shows the percentage improvement in 
the dose-volume statistics of interest when the CNS objectives were 
introduced. 
 
 
Figure 1: Percentage improvement in dose-volume statistics for the 
CNS structures upon introducing the CNS objectives. The white values 
indicate where the proposed constraints were achieved. For Hyp – 2 
the CNS constraints were already achieved prior to introducing the 
additional objectives into the plan optimisation. Many, but not all, of 
the CNS constraints could be achieved for most patients. Fewer 
constraints could be achieved for nasopharyngeal primaries compared 
with oropharyngeal and hypopharyngeal cancers. 3D dose analysis 
indicated that the dose reduction to the CNS structures resulted in 
consistent patterns of increased doses to uncontoured regions in the 
neck. 
Conclusions: It has been demonstrated that it is feasible to 
implement constraints to reduce the dose-distribution to the 
brainstem and cerebellum without compromising tumour coverage or 
sparing of organs at risk. However, the increased doses delivered to 
the neck should be carefully considered when assessing the dose-
distributions of plans produced using this technique. 
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